Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting
June 19th, 2008
EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced the presentation of clinical data for the MKC-1 Phase 2 study in patients with metastatic breast cancer. The data were presented by Bryan P. Schneider, M.D., Assistant Professor, Department of Medicine, Indiana University, during the Breast Cancer -- Metastatic session at the American Society of Clinical Oncology Annual Meeting being held this week in Chicago, Illinois. For this Phase 2 single agent, open label study, a total of 65 patients who had previously received at least one anthracycline and taxane therapy...
Source: Women's Health Weekly (2008-06-19)
|
